Overactive bladder is a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are considered as the first line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are some of the generic drugs used for the treatment of overactive bladder. These drugs acts by antagonizing cholinergic receptors that provides the relief from the frequent urination.
The global Overactive Bladder (OAB) Therapeutics market size is projected to reach US$ 3585.5 million by 2027, from US$ 3251.3 million in 2020, at a CAGR of 1.6% during 2022-2027.
The global Overactive Bladder (OAB) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Overactive Bladder (OAB) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Increasing population diagnosed with overactive bladder disorder coupled with aging population will drive the growth of this market. Furthermore, manufacturers are continuously increasing their research and development expenditure to develop novel drugs such as neuromuscular blocking agents with innovative mechanism of actions. This factor will provide healthy platform to develop this market and hence drives the market growth.
Geographical Analysis:
Based on region, the global Overactive Bladder (OAB) Therapeutics market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Overactive Bladder (OAB) Therapeutics market are
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries
Segment by Type
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Segment by Application
Hosptial
Clinci
Other
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Overactive Bladder (OAB) Therapeutics market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Overactive Bladder (OAB) Therapeutics market.
• The market share of the global Overactive Bladder (OAB) Therapeutics market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Overactive Bladder (OAB) Therapeutics market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Overactive Bladder (OAB) Therapeutics market.
The global Overactive Bladder (OAB) Therapeutics market size is projected to reach US$ 3585.5 million by 2027, from US$ 3251.3 million in 2020, at a CAGR of 1.6% during 2022-2027.
The global Overactive Bladder (OAB) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Overactive Bladder (OAB) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Increasing population diagnosed with overactive bladder disorder coupled with aging population will drive the growth of this market. Furthermore, manufacturers are continuously increasing their research and development expenditure to develop novel drugs such as neuromuscular blocking agents with innovative mechanism of actions. This factor will provide healthy platform to develop this market and hence drives the market growth.
Geographical Analysis:
Based on region, the global Overactive Bladder (OAB) Therapeutics market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Overactive Bladder (OAB) Therapeutics market are
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries
Segment by Type
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Segment by Application
Hosptial
Clinci
Other
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Overactive Bladder (OAB) Therapeutics market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Overactive Bladder (OAB) Therapeutics market.
• The market share of the global Overactive Bladder (OAB) Therapeutics market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Overactive Bladder (OAB) Therapeutics market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Overactive Bladder (OAB) Therapeutics market.
1 Overactive Bladder (OAB) Therapeutics Market Overview
1.1 Overactive Bladder (OAB) Therapeutics Product Scope
1.2 Overactive Bladder (OAB) Therapeutics Segment by Type
1.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2016 & 2021 & 2027)
1.2.2 Anticholinergic Agents
1.2.3 Beta-3 Adrenoreceptor Agonists
1.3 Overactive Bladder (OAB) Therapeutics Segment by Application
1.3.1 Global Overactive Bladder (OAB) Therapeutics Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hosptial
1.3.3 Clinci
1.3.4 Other
1.4 Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts (2016-2027)
1.4.1 Global Overactive Bladder (OAB) Therapeutics Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Overactive Bladder (OAB) Therapeutics Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Overactive Bladder (OAB) Therapeutics Price Trends (2016-2027)
2 Overactive Bladder (OAB) Therapeutics Estimates and Forecasts by Region
2.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2016-2021)
2.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2016-2021)
2.3 Global Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Overactive Bladder (OAB) Therapeutics Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
2.4.2 Europe Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
2.4.3 China Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
2.4.4 Japan Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
2.4.6 India Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
3 Global Overactive Bladder (OAB) Therapeutics Competition Landscape by Players
3.1 Global Top Overactive Bladder (OAB) Therapeutics Players by Sales (2016-2021)
3.2 Global Top Overactive Bladder (OAB) Therapeutics Players by Revenue (2016-2021)
3.3 Global Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Overactive Bladder (OAB) Therapeutics as of 2020)
3.4 Global Overactive Bladder (OAB) Therapeutics Average Price by Company (2016-2021)
3.5 Manufacturers Overactive Bladder (OAB) Therapeutics Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Overactive Bladder (OAB) Therapeutics Market Size by Type
4.1 Global Overactive Bladder (OAB) Therapeutics Historic Market Review by Type (2016-2021)
4.1.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2016-2021)
4.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2016-2021)
4.1.3 Global Overactive Bladder (OAB) Therapeutics Price by Type (2016-2021)
4.2 Global Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Type (2022-2027)
4.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Type (2022-2027)
4.2.3 Global Overactive Bladder (OAB) Therapeutics Price Forecast by Type (2022-2027)
5 Global Overactive Bladder (OAB) Therapeutics Market Size by Application
5.1 Global Overactive Bladder (OAB) Therapeutics Historic Market Review by Application (2016-2021)
5.1.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2016-2021)
5.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2016-2021)
5.1.3 Global Overactive Bladder (OAB) Therapeutics Price by Application (2016-2021)
5.2 Global Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Application (2022-2027)
5.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Application (2022-2027)
5.2.3 Global Overactive Bladder (OAB) Therapeutics Price Forecast by Application (2022-2027)
6 North America Overactive Bladder (OAB) Therapeutics Market Facts & Figures
6.1 North America Overactive Bladder (OAB) Therapeutics Sales by Company
6.1.1 North America Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
6.1.2 North America Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
6.2 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
6.2.1 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
6.2.2 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
6.3 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
6.3.1 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2016-2021)
6.3.2 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2022-2027)
7 Europe Overactive Bladder (OAB) Therapeutics Market Facts & Figures
7.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Company
7.1.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
7.1.2 Europe Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
7.2 Europe Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
7.2.1 Europe Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
7.2.2 Europe Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
7.3 Europe Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
7.3.1 Europe 129 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 129 Sales Breakdown by Application (2022-2027)
8 China Overactive Bladder (OAB) Therapeutics Market Facts & Figures
8.1 China Overactive Bladder (OAB) Therapeutics Sales by Company
8.1.1 China Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
8.1.2 China Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
8.2 China Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
8.2.1 China Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
8.2.2 China Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
8.3 China Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
8.3.1 China 155 Sales Breakdown by Application (2016-2021)
8.3.2 China 155 Sales Breakdown by Application (2022-2027)
9 Japan Overactive Bladder (OAB) Therapeutics Market Facts & Figures
9.1 Japan Overactive Bladder (OAB) Therapeutics Sales by Company
9.1.1 Japan Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
9.1.2 Japan Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
9.2 Japan Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
9.2.1 Japan Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
9.2.2 Japan Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
9.3 Japan Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
9.3.1 Japan Mar. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Mar. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Overactive Bladder (OAB) Therapeutics Market Facts & Figures
10.1 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales by Company
10.1.1 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
10.1.2 Southeast Asia Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
10.2 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
10.2.1 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
10.3.1 Southeast Asia Kg Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia Kg Sales Breakdown by Application (2022-2027)
11 India Overactive Bladder (OAB) Therapeutics Market Facts & Figures
11.1 India Overactive Bladder (OAB) Therapeutics Sales by Company
11.1.1 India Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
11.1.2 India Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
11.2 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
11.2.1 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
11.2.2 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
11.3 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
11.3.1 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2016-2021)
11.3.2 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Overactive Bladder (OAB) Therapeutics Business
12.1 Allergan
12.1.1 Allergan Corporation Information
12.1.2 Allergan Business Overview
12.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Allergan Overactive Bladder (OAB) Therapeutics Products Offered
12.1.5 Allergan Recent Development
12.2 Astellas Pharma
12.2.1 Astellas Pharma Corporation Information
12.2.2 Astellas Pharma Business Overview
12.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Products Offered
12.2.5 Astellas Pharma Recent Development
12.3 Hisamitsu Pharmaceutical
12.3.1 Hisamitsu Pharmaceutical Corporation Information
12.3.2 Hisamitsu Pharmaceutical Business Overview
12.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
12.3.5 Hisamitsu Pharmaceutical Recent Development
12.4 Pfizer
12.4.1 Pfizer Corporation Information
12.4.2 Pfizer Business Overview
12.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Products Offered
12.4.5 Pfizer Recent Development
12.5 Ferring
12.5.1 Ferring Corporation Information
12.5.2 Ferring Business Overview
12.5.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Ferring Overactive Bladder (OAB) Therapeutics Products Offered
12.5.5 Ferring Recent Development
12.6 GlaxoSmithKline
12.6.1 GlaxoSmithKline Corporation Information
12.6.2 GlaxoSmithKline Business Overview
12.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Products Offered
12.6.5 GlaxoSmithKline Recent Development
12.7 Ion Channel Innovations
12.7.1 Ion Channel Innovations Corporation Information
12.7.2 Ion Channel Innovations Business Overview
12.7.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Products Offered
12.7.5 Ion Channel Innovations Recent Development
12.8 Kwang Dong Pharmaceutical
12.8.1 Kwang Dong Pharmaceutical Corporation Information
12.8.2 Kwang Dong Pharmaceutical Business Overview
12.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
12.8.5 Kwang Dong Pharmaceutical Recent Development
12.9 Lanzhou Institute of Biological Products
12.9.1 Lanzhou Institute of Biological Products Corporation Information
12.9.2 Lanzhou Institute of Biological Products Business Overview
12.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Products Offered
12.9.5 Lanzhou Institute of Biological Products Recent Development
12.10 Merck
12.10.1 Merck Corporation Information
12.10.2 Merck Business Overview
12.10.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Merck Overactive Bladder (OAB) Therapeutics Products Offered
12.10.5 Merck Recent Development
12.11 ONO Pharmaceutical
12.11.1 ONO Pharmaceutical Corporation Information
12.11.2 ONO Pharmaceutical Business Overview
12.11.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.11.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
12.11.5 ONO Pharmaceutical Recent Development
12.12 Sanofi
12.12.1 Sanofi Corporation Information
12.12.2 Sanofi Business Overview
12.12.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Sanofi Overactive Bladder (OAB) Therapeutics Products Offered
12.12.5 Sanofi Recent Development
12.13 Tengion
12.13.1 Tengion Corporation Information
12.13.2 Tengion Business Overview
12.13.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Tengion Overactive Bladder (OAB) Therapeutics Products Offered
12.13.5 Tengion Recent Development
12.14 Teva Pharmaceutical Industries
12.14.1 Teva Pharmaceutical Industries Corporation Information
12.14.2 Teva Pharmaceutical Industries Business Overview
12.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Products Offered
12.14.5 Teva Pharmaceutical Industries Recent Development
13 Overactive Bladder (OAB) Therapeutics Manufacturing Cost Analysis
13.1 Overactive Bladder (OAB) Therapeutics Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Overactive Bladder (OAB) Therapeutics
13.4 Overactive Bladder (OAB) Therapeutics Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Overactive Bladder (OAB) Therapeutics Distributors List
14.3 Overactive Bladder (OAB) Therapeutics Customers
15 Market Dynamics
15.1 Overactive Bladder (OAB) Therapeutics Market Trends
15.2 Overactive Bladder (OAB) Therapeutics Drivers
15.3 Overactive Bladder (OAB) Therapeutics Market Challenges
15.4 Overactive Bladder (OAB) Therapeutics Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
1.1 Overactive Bladder (OAB) Therapeutics Product Scope
1.2 Overactive Bladder (OAB) Therapeutics Segment by Type
1.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2016 & 2021 & 2027)
1.2.2 Anticholinergic Agents
1.2.3 Beta-3 Adrenoreceptor Agonists
1.3 Overactive Bladder (OAB) Therapeutics Segment by Application
1.3.1 Global Overactive Bladder (OAB) Therapeutics Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hosptial
1.3.3 Clinci
1.3.4 Other
1.4 Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts (2016-2027)
1.4.1 Global Overactive Bladder (OAB) Therapeutics Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Overactive Bladder (OAB) Therapeutics Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Overactive Bladder (OAB) Therapeutics Price Trends (2016-2027)
2 Overactive Bladder (OAB) Therapeutics Estimates and Forecasts by Region
2.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Overactive Bladder (OAB) Therapeutics Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2016-2021)
2.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2016-2021)
2.3 Global Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Overactive Bladder (OAB) Therapeutics Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
2.4.2 Europe Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
2.4.3 China Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
2.4.4 Japan Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
2.4.6 India Overactive Bladder (OAB) Therapeutics Estimates and Projections (2016-2027)
3 Global Overactive Bladder (OAB) Therapeutics Competition Landscape by Players
3.1 Global Top Overactive Bladder (OAB) Therapeutics Players by Sales (2016-2021)
3.2 Global Top Overactive Bladder (OAB) Therapeutics Players by Revenue (2016-2021)
3.3 Global Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Overactive Bladder (OAB) Therapeutics as of 2020)
3.4 Global Overactive Bladder (OAB) Therapeutics Average Price by Company (2016-2021)
3.5 Manufacturers Overactive Bladder (OAB) Therapeutics Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Overactive Bladder (OAB) Therapeutics Market Size by Type
4.1 Global Overactive Bladder (OAB) Therapeutics Historic Market Review by Type (2016-2021)
4.1.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2016-2021)
4.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2016-2021)
4.1.3 Global Overactive Bladder (OAB) Therapeutics Price by Type (2016-2021)
4.2 Global Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Type (2022-2027)
4.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Type (2022-2027)
4.2.3 Global Overactive Bladder (OAB) Therapeutics Price Forecast by Type (2022-2027)
5 Global Overactive Bladder (OAB) Therapeutics Market Size by Application
5.1 Global Overactive Bladder (OAB) Therapeutics Historic Market Review by Application (2016-2021)
5.1.1 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2016-2021)
5.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2016-2021)
5.1.3 Global Overactive Bladder (OAB) Therapeutics Price by Application (2016-2021)
5.2 Global Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Application (2022-2027)
5.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue Forecast by Application (2022-2027)
5.2.3 Global Overactive Bladder (OAB) Therapeutics Price Forecast by Application (2022-2027)
6 North America Overactive Bladder (OAB) Therapeutics Market Facts & Figures
6.1 North America Overactive Bladder (OAB) Therapeutics Sales by Company
6.1.1 North America Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
6.1.2 North America Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
6.2 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
6.2.1 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
6.2.2 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
6.3 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
6.3.1 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2016-2021)
6.3.2 North America Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2022-2027)
7 Europe Overactive Bladder (OAB) Therapeutics Market Facts & Figures
7.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Company
7.1.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
7.1.2 Europe Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
7.2 Europe Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
7.2.1 Europe Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
7.2.2 Europe Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
7.3 Europe Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
7.3.1 Europe 129 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 129 Sales Breakdown by Application (2022-2027)
8 China Overactive Bladder (OAB) Therapeutics Market Facts & Figures
8.1 China Overactive Bladder (OAB) Therapeutics Sales by Company
8.1.1 China Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
8.1.2 China Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
8.2 China Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
8.2.1 China Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
8.2.2 China Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
8.3 China Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
8.3.1 China 155 Sales Breakdown by Application (2016-2021)
8.3.2 China 155 Sales Breakdown by Application (2022-2027)
9 Japan Overactive Bladder (OAB) Therapeutics Market Facts & Figures
9.1 Japan Overactive Bladder (OAB) Therapeutics Sales by Company
9.1.1 Japan Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
9.1.2 Japan Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
9.2 Japan Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
9.2.1 Japan Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
9.2.2 Japan Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
9.3 Japan Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
9.3.1 Japan Mar. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Mar. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Overactive Bladder (OAB) Therapeutics Market Facts & Figures
10.1 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales by Company
10.1.1 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
10.1.2 Southeast Asia Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
10.2 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
10.2.1 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
10.3.1 Southeast Asia Kg Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia Kg Sales Breakdown by Application (2022-2027)
11 India Overactive Bladder (OAB) Therapeutics Market Facts & Figures
11.1 India Overactive Bladder (OAB) Therapeutics Sales by Company
11.1.1 India Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2021)
11.1.2 India Overactive Bladder (OAB) Therapeutics Revenue by Company (2016-2021)
11.2 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type
11.2.1 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2016-2021)
11.2.2 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Type (2022-2027)
11.3 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application
11.3.1 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2016-2021)
11.3.2 India Overactive Bladder (OAB) Therapeutics Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Overactive Bladder (OAB) Therapeutics Business
12.1 Allergan
12.1.1 Allergan Corporation Information
12.1.2 Allergan Business Overview
12.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Allergan Overactive Bladder (OAB) Therapeutics Products Offered
12.1.5 Allergan Recent Development
12.2 Astellas Pharma
12.2.1 Astellas Pharma Corporation Information
12.2.2 Astellas Pharma Business Overview
12.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Products Offered
12.2.5 Astellas Pharma Recent Development
12.3 Hisamitsu Pharmaceutical
12.3.1 Hisamitsu Pharmaceutical Corporation Information
12.3.2 Hisamitsu Pharmaceutical Business Overview
12.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
12.3.5 Hisamitsu Pharmaceutical Recent Development
12.4 Pfizer
12.4.1 Pfizer Corporation Information
12.4.2 Pfizer Business Overview
12.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Products Offered
12.4.5 Pfizer Recent Development
12.5 Ferring
12.5.1 Ferring Corporation Information
12.5.2 Ferring Business Overview
12.5.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Ferring Overactive Bladder (OAB) Therapeutics Products Offered
12.5.5 Ferring Recent Development
12.6 GlaxoSmithKline
12.6.1 GlaxoSmithKline Corporation Information
12.6.2 GlaxoSmithKline Business Overview
12.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Products Offered
12.6.5 GlaxoSmithKline Recent Development
12.7 Ion Channel Innovations
12.7.1 Ion Channel Innovations Corporation Information
12.7.2 Ion Channel Innovations Business Overview
12.7.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Products Offered
12.7.5 Ion Channel Innovations Recent Development
12.8 Kwang Dong Pharmaceutical
12.8.1 Kwang Dong Pharmaceutical Corporation Information
12.8.2 Kwang Dong Pharmaceutical Business Overview
12.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
12.8.5 Kwang Dong Pharmaceutical Recent Development
12.9 Lanzhou Institute of Biological Products
12.9.1 Lanzhou Institute of Biological Products Corporation Information
12.9.2 Lanzhou Institute of Biological Products Business Overview
12.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Products Offered
12.9.5 Lanzhou Institute of Biological Products Recent Development
12.10 Merck
12.10.1 Merck Corporation Information
12.10.2 Merck Business Overview
12.10.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Merck Overactive Bladder (OAB) Therapeutics Products Offered
12.10.5 Merck Recent Development
12.11 ONO Pharmaceutical
12.11.1 ONO Pharmaceutical Corporation Information
12.11.2 ONO Pharmaceutical Business Overview
12.11.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.11.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Products Offered
12.11.5 ONO Pharmaceutical Recent Development
12.12 Sanofi
12.12.1 Sanofi Corporation Information
12.12.2 Sanofi Business Overview
12.12.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Sanofi Overactive Bladder (OAB) Therapeutics Products Offered
12.12.5 Sanofi Recent Development
12.13 Tengion
12.13.1 Tengion Corporation Information
12.13.2 Tengion Business Overview
12.13.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Tengion Overactive Bladder (OAB) Therapeutics Products Offered
12.13.5 Tengion Recent Development
12.14 Teva Pharmaceutical Industries
12.14.1 Teva Pharmaceutical Industries Corporation Information
12.14.2 Teva Pharmaceutical Industries Business Overview
12.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Products Offered
12.14.5 Teva Pharmaceutical Industries Recent Development
13 Overactive Bladder (OAB) Therapeutics Manufacturing Cost Analysis
13.1 Overactive Bladder (OAB) Therapeutics Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Overactive Bladder (OAB) Therapeutics
13.4 Overactive Bladder (OAB) Therapeutics Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Overactive Bladder (OAB) Therapeutics Distributors List
14.3 Overactive Bladder (OAB) Therapeutics Customers
15 Market Dynamics
15.1 Overactive Bladder (OAB) Therapeutics Market Trends
15.2 Overactive Bladder (OAB) Therapeutics Drivers
15.3 Overactive Bladder (OAB) Therapeutics Market Challenges
15.4 Overactive Bladder (OAB) Therapeutics Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
